CVI Pharmaceuticals Ltd. has identified thyroid hormone receptor (THR)-β agonists reported to be useful for the treatment of atherosclerosis, hypercholesterolemia, hyperlipidemia, hepatic steatosis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results